BioNTech SE(CH:22UA)
CHF 72.300.00 (0.00%)
CH:22UA
BioNTech SE stock forecast
CHF 72.30
At close:0.00 (0.00%)
BioNTech SE (22UA) Stock Forecast & Price Target
1 Followers
22UA Analyst Ratings
Strong Buy
12Buy4Hold0Sell
Based on 16 analysts giving stock ratings to BioNTech SE in the past 3 months
22UA Stock 12 Month Forecast
Average Price Target
CHF100.05▲(38.38% Upside)Based on 16 Wall Street analysts offering 12 month price targets for BioNTech SE in the last 3 months. The average price target is CHF 100.05 with a high forecast of CHF 115.56 and a low forecast of CHF 78.42. The average price target represents a 38.38% change from the last price of CHF 72.30.
Past 12 Months12 Month ForecastJan2026Oct2026
HighCHF115.56
AverageCHF100.05
LowCHF78.42
Highest Price TargetHighestCHF115.56Average Price TargetCHF100.05Lowest Price TargetLowestCHF78.42
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Geoff Meacham | Citi | CHF103.18 | buy | 42.71%Upside | Reiterated | 11/11/26 | ||
| Robert Burns | H.C. Wainwright | CHF107.31→CHF90.80 | buy | 25.58%Upside | Reiterated | 11/10/26 | ||
| Terence Flynn | Morgan Stanley | CHF87.50 | buy | 21.02%Upside | Assigned | 11/09/26 | ||
| Jeffrey Walch | Bernstein | CHF79.24 | hold | 9.60%Upside | Reiterated | 11/06/26 | ||
| Akash Tewari | Jefferies | CHF113.91 | buy | 57.55%Upside | Reiterated | 11/04/26 | ||
| John Newman | Canaccord Genuity | CHF108.96 | buy | 50.70%Upside | Reiterated | 11/04/26 | ||
| David Dai | UBS | CHF111.43→CHF103.18 | buy | 42.71%Upside | Reiterated | 11/04/26 | ||
| Mohit Bansal | Wells Fargo | CHF115.56→CHF103.18 | buy | 42.71%Upside | Reiterated | 11/04/26 | ||
| Asad Haider | Goldman Sachs | CHF104.83 | buy | 44.99%Upside | Reiterated | 11/04/26 | ||
| Tazeen Ahmad | Bank of America Securities | CHF94.10→CHF89.15 | buy | 23.30%Upside | Reiterated | 11/03/26 | ||
| Evan Seigerman | BMO Capital | CHF86.67→CHF78.42 | hold | 8.46%Upside | Assigned | 11/03/26 | ||
| Jessica Fye | J.P. Morgan | ― | hold | ― | Reiterated | 10/27/26 | ||
| Cory Kasimov | Evercore ISI | CHF107.31 | buy | 48.41%Upside | Reiterated | 10/13/26 | ||
| Harry Gillis | Berenberg Bank | CHF115.56 | buy | 59.83%Upside | Reiterated | 10/07/26 | ||
| John Eade | Argus Research | ― | hold | ― | Initiated | 10/07/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Geoff MeachamCiti | BuyReiteratedCHF103.18 | 11/11/26 | 42.71%Upside | ||
| Robert BurnsH.C. Wainwright | BuyReiteratedCHF107.31→CHF90.80 | 11/10/26 | 25.58%Upside | ||
| Terence FlynnMorgan Stanley | BuyAssignedCHF87.50 | 11/09/26 | 21.02%Upside | ||
| Jeffrey WalchBernstein | HoldReiteratedCHF79.24 | 11/06/26 | 9.60%Upside | ||
| Akash TewariJefferies | BuyReiteratedCHF113.91 | 11/04/26 | 57.55%Upside | ||
| John NewmanCanaccord Genuity | BuyReiteratedCHF108.96 | 11/04/26 | 50.70%Upside | ||
| David DaiUBS | BuyReiteratedCHF111.43→CHF103.18 | 11/04/26 | 42.71%Upside | ||
| Mohit BansalWells Fargo | BuyReiteratedCHF115.56→CHF103.18 | 11/04/26 | 42.71%Upside | ||
| Asad HaiderGoldman Sachs | BuyReiteratedCHF104.83 | 11/04/26 | 44.99%Upside | ||
| Tazeen AhmadBank of America Securities | BuyReiteratedCHF94.10→CHF89.15 | 11/03/26 | 23.30%Upside | ||
| Evan SeigermanBMO Capital | HoldAssignedCHF86.67→CHF78.42 | 11/03/26 | 8.46%Upside | ||
| Jessica FyeJ.P. Morgan | HoldReiterated | 10/27/26 | ― | ||
| Cory KasimovEvercore ISI | BuyReiteratedCHF107.31 | 10/13/26 | 48.41%Upside | ||
| Harry GillisBerenberg Bank | BuyReiteratedCHF115.56 | 10/07/26 | 59.83%Upside | ||
| John EadeArgus Research | HoldInitiated | 10/07/26 | ― |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering BioNTech SE
3 Months
Success Rate9/16 ratings generated profit
56%
Average Return
+3.28%
Copying Akash Tewari's trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of +3.28% per trade.
1 Year
Success Rate9/21 ratings generated profit
43%
Average Return
+0.49%
Copying Robert Burns's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of +0.49% per trade.
2 Years
Success Rate7/21 ratings generated profit
33%
Average Return
-5.17%
Copying Robert Burns's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -5.17% per trade.
22UA Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 8 | 6 | 4 | 5 | 3 |
| Buy | 10 | 21 | 33 | 48 | 39 |
| Hold | 5 | 5 | 6 | 9 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 23 | 32 | 43 | 62 | 50 |
In the current month, 22UA has received 42 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. 22UA average Analyst price target in the past 3 months is 100.05.
22UA Financial Forecast
HighCHF-0.94
ConsensusCHF-1.58
LowCHF-2.92
22UA Earnings Forecast
Next quarter’s earnings estimate for 22UA is -CHF 1.58 with a range of -CHF 2.92 to -CHF 0.94. The previous quarter’s EPS was CHF 0.67. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighCHF554M
ConsensusCHF356M
LowCHF257M
22UA Sales Forecast
Next quarter’s sales forecast for 22UA is CHF 356.17M with a range of CHF 257.20M to CHF 553.89M. The previous quarter’s sales results were CHF 1.23B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
22UA Stock Forecast FAQ
What is CH:22UA’s average 12-month price target, according to analysts?
Based on analyst ratings, BioNTech SE’s 12-month average price target is CHF100.05.
What is CH:22UA’s upside potential, based on the analysts’ average price target?
BioNTech SE has 38.38% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BioNTech SE a Buy, Sell or Hold?
BioNTech SE has a consensus rating of Strong Buy, which is based on 12 buy ratings, 4 hold ratings and 0 sell ratings.
What is BioNTech SE’s share price target?
The average share price target for BioNTech SE is CHF100.05. This is based on 16 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is CHF115.56, and the lowest forecast is CHF78.42. The average share price target represents a 38.38% increase from the current price of CHF72.301.
What do analysts say about BioNTech SE?
BioNTech SE’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Street analysts.
How can I buy shares of BioNTech SE?
To buy shares of CH:22UA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
